Century Therapeutics, Inc. (IPSC)
Nasdaq: IPSC · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2021
Who owns Century Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
RA Capital Management, L.P. holds 9.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G filed Jan 16, 2026 says.
Directors and officers
10
report now, of 21 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13G · filed Jan 16, 2026 · Common Stock, par value $0.0001 per share
Chen Yu
SCHEDULE 13G · filed Jan 15, 2026 · Common Stock, par value $0.0001 per share
Deep Track Capital, LP
SCHEDULE 13G · filed Jan 15, 2026 · Common Stock, par value $0.0001 per share
RTW Investments, LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, $0.0001 par value
Commodore Capital LP
SCHEDULE 13G · filed Jan 16, 2026 · Common Stock, par value $0.0001 per share
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G · filed Jan 16, 2026 · Common Stock, par value $0.0001 per share · 4.7% in Feb 14, 2025
Bain Capital Life Sciences Opportunities III, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Casdin Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.8% in Feb 17, 2026
What IPSC reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Clade Therapeutics, Inc.
A company bought · acquisition · owns, named in the 10-K filed Mar 12, 2026
4 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 12, 2026.
Insider tradesForm 4
20sales
3purchases
0sales on a scheduled plan
4people selling
$100,000sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Pfeiffenberger Brent | President and CEO | 1 | $0 | 0 | 2 | $0 |
| Cowan Chad | Chief Scientific Officer | 1 | $0 | 0 | 1 | $0 |
| Russotti Gregory | Title: Chief Technology and Manufacturing Officer | 7 | $0 | 0 | 0 | $0 |
| Carr Douglas | SVP Finance & Operations | 11 | $0 | 0 | 0 | $0 |